Cynk-001 clinical trial
WebMar 18, 2024 · CYNK-001 is a non-genetically modified cryopreserved allogeneic placental hematopoietic stem cell-derived NK cell therapy that is being investigated as an off-the …
Cynk-001 clinical trial
Did you know?
WebCYNK-001 is the only cryopreserved allogeneic, off-the-shelf NK cell therapy developed from placental hematopoietic stem cells. CYNK-001 is being investigated as a potential treatment option in adults with COVID-19, as well as for … WebJun 2, 2024 · Background: CYNK-001 is a CD56+CD3- enriched, off-the-shelf, allogeneic natural killer (NK) cell product expanded from placental CD34 cells. CYNK-001 exhibits …
WebDec 29, 2024 · CYNK-001 contains NK cells derived from human placental CD34+ cells and culture-expanded. In a new phase 1 multi-dose study (NCT04310592) of approximately 56 adult patients with AML, CYNK-001 cells will be given after lymphodepleting chemotherapy to determine its safety and whether NK cells be used to treat AML. 1,2 WebApr 28, 2024 · Brief Summary: This study is a Phase 1 / 2 trial to determine the safety and efficacy of CYNK-001, an immunotherapy containing Natural Killer (NK) cells derived …
WebJul 1, 2024 · Background CYNK-001 is a cryopreserved, allogeneic, off-the-shelf natural killer (NK) cell investigational product derived from placental CD34+ cells. CYNK-001 … WebThis study will find the maximum tolerated dose or the maximum planned dose of CYNK-001 which contains natural killer (NK) cells derived from human placental CD34+ cells and culture-expanded. CYNK-001 cells will be given after lymphodepleting chemotherapy. The safety of this treatment will be evaluated, and researchers want to learn if NK cells ...
WebJan 4, 2024 · CYNK-001 is the only cryopreserved allogeneic, off-the-shelf NK cell therapy that incorporates CD56-positive and CD3-negative NK cells expanded from human placental CD34-positive cells and is being …
WebThe purpose of this clinical research study is to evaluate the safety (any good or bad effects) of CYNK-001 and to assess the effects of CYNK-001 on your Acute Myeloid Leukemia … biographic information for deferred actionWebestimated completion June 2024 Description Summary This study is a Phase 1 / 2 trial to determine the safety and efficacy of CYNK-001, an immunotherapy containing Natural Killer (NK) cells derived from human placental CD34+ cells and culture-expanded, in patients with moderate COVID-19 disease. Official Title biographic differencesWebCYNK-001 is the only cryopreserved allogeneic, off-the-shelf NK cell therapy developed from placental hematopoietic stem cells. CYNK-001 is being investigated as a potential … biographic formWebAug 5, 2024 · The first co-primary endpoint is to determine the virologic efficacy of CYNK-001 in facilitating the clearance of SARS-CoV-2 from mucosal specimens and/or peripheral blood. The second co-primary endpoint is to assess the impact of treatment with CYNK-001 on clinical symptoms among patients with COVID-19 related lower respiratory tract … biographic information meaningWebApr 2, 2024 · “We congratulate Celularity’s rapid progress in moving CYNK-001 from immune-oncology applications to a COVID-19 clinical trial since our first announcement of the collaboration on January 29, 2024. We will do whatever we can to assist Celularity in its fight against COVID-19 pandemic.” About Sorrento Therapeutics, Inc. biographic filmsWebCYNK-001 cells will be given after lymphodepleting chemotherapy. The safety of this treatment will be evaluated, and researchers want to learn if NK cells will help in treating … biographic dollWebSep 8, 2024 · CYNK-001 is being investigated as a potential treatment option in adults with COVID-19, as well as for various hematologic cancers and solid tumors. biographic information def